MA51840A - Modulateurs de somatostatine et leurs utilisations - Google Patents

Modulateurs de somatostatine et leurs utilisations

Info

Publication number
MA51840A
MA51840A MA051840A MA51840A MA51840A MA 51840 A MA51840 A MA 51840A MA 051840 A MA051840 A MA 051840A MA 51840 A MA51840 A MA 51840A MA 51840 A MA51840 A MA 51840A
Authority
MA
Morocco
Prior art keywords
somatostatin modulators
somatostatin
modulators
Prior art date
Application number
MA051840A
Other languages
English (en)
Inventor
Shimiao Wang
Jian Zhao
Yunfei Zhu
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of MA51840A publication Critical patent/MA51840A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA051840A 2018-02-12 2019-02-11 Modulateurs de somatostatine et leurs utilisations MA51840A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629377P 2018-02-12 2018-02-12
US201862673042P 2018-05-17 2018-05-17
US201862724421P 2018-08-29 2018-08-29

Publications (1)

Publication Number Publication Date
MA51840A true MA51840A (fr) 2021-05-19

Family

ID=67548490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051840A MA51840A (fr) 2018-02-12 2019-02-11 Modulateurs de somatostatine et leurs utilisations

Country Status (5)

Country Link
US (1) US11608335B2 (fr)
EP (1) EP3752498B1 (fr)
JP (1) JP7365347B2 (fr)
MA (1) MA51840A (fr)
WO (1) WO2019157458A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908512YA (en) 2017-03-16 2019-10-30 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
JP7365347B2 (ja) 2018-02-12 2023-10-19 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターおよびその使用
JP7431813B2 (ja) 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
JP2022544055A (ja) 2019-08-14 2022-10-17 クリネティックス ファーマシューティカルズ，インク． 非ペプチドソマトスタチン５型受容体アゴニストおよびその使用
WO2022177988A1 (fr) * 2021-02-17 2022-08-25 Crinetics Pharmaceuticals, Inc. Agoniste type 5 du récepteur de la somatostatine pour traiter l'hyperinsulinisme
US11773076B2 (en) 2021-02-17 2023-10-03 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
WO2024089668A1 (fr) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Agonistes du récepteur 2 de la somatostatine et leurs utilisations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20060281764A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
WO2008051272A2 (fr) 2006-03-13 2008-05-02 Merck & Co., Inc. Agonistes de somatostatine
CA2658960A1 (fr) 2006-08-15 2008-02-21 Alfred Binggeli Derives phenyliques, de la pyridine et de la quinoleine
US20100227845A1 (en) 2007-10-18 2010-09-09 Zhicai Wu Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
CN102131798A (zh) 2008-06-25 2011-07-20 英维沃医药有限公司 用作磷酸二酯酶10抑制剂的二取代的苯基化合物
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
CA2772194A1 (fr) 2009-09-01 2011-03-10 Pfizer Inc. Derives de benzimidazole
US20130040978A1 (en) 2010-05-18 2013-02-14 Joseph L. Duffy Spiro isoxazoline compounds as sstr5 antagonists
GB201008290D0 (en) 2010-05-18 2010-06-30 Syngenta Ltd Chemical compounds
EP2871179A4 (fr) 2012-07-03 2016-03-16 Ono Pharmaceutical Co Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales
PT3053916T (pt) 2013-09-30 2019-03-26 Ono Pharmaceutical Co Composto com atividade agonista do recetor da somatostatina e utiliza ao farmaceutica do mesmo
EP3053961B1 (fr) 2013-10-02 2018-06-06 Kuraray Co., Ltd. Composition de résine, feuille multicouches, matériau d'emballage et conteneur
PT3484865T (pt) 2016-07-14 2022-11-03 Crinetics Pharmaceuticals Inc Moduladores da somatostatina e suas utilizações
RU2019124888A (ru) 2017-02-08 2021-03-10 Оно Фармасьютикал Ко., Лтд. Соединение, имеющее агонистическую активность в отношении рецептора соматостатина, и его фармацевтическое применение
SG11201908512YA (en) * 2017-03-16 2019-10-30 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
EP3658560A4 (fr) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et utilisations de ces derniers
JP7365347B2 (ja) 2018-02-12 2023-10-19 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターおよびその使用
JP7431813B2 (ja) 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
JP2022544055A (ja) 2019-08-14 2022-10-17 クリネティックス ファーマシューティカルズ，インク． 非ペプチドソマトスタチン５型受容体アゴニストおよびその使用

Also Published As

Publication number Publication date
JP7365347B2 (ja) 2023-10-19
JP2021512889A (ja) 2021-05-20
EP3752498B1 (fr) 2023-06-28
EP3752498A1 (fr) 2020-12-23
US11608335B2 (en) 2023-03-21
US20210040087A1 (en) 2021-02-11
WO2019157458A1 (fr) 2019-08-15
EP3752498A4 (fr) 2021-11-03

Similar Documents

Publication Publication Date Title
MA51840A (fr) Modulateurs de somatostatine et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
MA55627A (fr) Agonistes de glp-1r et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA52483A (fr) Dérivés de gip et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA53660A (fr) Analogues de stérol et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA55083A (fr) Polyribonucléotides et leurs utilisations cosmétiques
MA51230A (fr) Protéines f rsv stabilisées et leurs utilisations
MA52365A (fr) Composés et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations